O-GlcNAc Glycosylation Antibodies: Decipher Novel Molecular Mechanisms Underlying Tumor Immune Evasion
Biological Significance of Dynamic O-GlcNAc Glycosylation in Tumor Progression
O-GlcNAcylation refers to reversible intracellular monosaccharide glycosylation catalyzed by OGT and erased by OGA hydrolase enzymes in mammalian cell systems.
This ubiquitous post-translational modification targets cytoplasmic and nuclear proteins to reshape folding, enzymatic activity and intermolecular binding interfaces.
Dysregulated global O-GlcNAc abundance emerges as a core hallmark of malignant cell phenotypes across multiple solid tumor model systems.
Aberrant glycosylation signaling coordinates three core oncogenic cascades: sustained proliferative capacity apoptotic resistance and tumor microenvironment immune suppression.
Metabolic fluctuations directly adjust UDP-GlcNAc substrate pools to shift global O-GlcNAc landscapes and rewire tumor adaptive transcriptional programs.
Site-specific glycosylation on single protein substrates can trigger divergent functional outputs, generating layered regulatory complexity in cancer signaling networks.
Site-Dependent Dual Functions of ENO1 O-GlcNAc Modification in Tumor Biology
Enolase 1 (ENO1) carries two distinct O-GlcNAc acceptor residues with completely separate downstream biological consequences.
Thr19 O-GlcNAcylation drives ENO1 homodimer assembly and elevates glycolytic catalytic turnover rates in tumor cell lysates.
Enhanced aerobic glycolysis amplifies lactate secretion to remodel the tumor microenvironment and suppress cytotoxic immune cell viability.
By contrast, Ser249 glycosylation disrupts stable physical interaction between ENO1 and PD-L1 protein substrates within tumor cytoplasm.
Disrupted ENO1-PD-L1 binding eliminates STUB E3 ligase-mediated ubiquitination to stabilize cell-surface PD-L1 protein pools.
Elevated PD-L1 expression strengthens PD-1 checkpoint signaling to inhibit T cell activation and establish robust tumor immune evasion phenotypes.
Core Experimental Roles of O-GlcNAc Specific Antibodies in Tumor Immunology Research
Site and pan O-GlcNAc targeted antibodies form irreplaceable analytical tools for multi-layered tumor glycosylation mechanism exploration.
-
Modification Locus Identification: Antibody-based immunoprecipitation coupled with LC-MS/MS precisely map O-GlcNAc acceptor residues on oncogenic proteins such as ENO1.
-
Spatial Expression Quantification: Immunohistochemistry and immunofluorescence detect global O-GlcNAc gradients in matched tumor and parenchymal tissue sections.
-
Functional State Discrimination: Validated antibodies distinguish glycosylated active protein conformers from unmodified inactive polypeptide isoforms.
-
Interactome Profiling: Co-IP workflows using anti-O-GlcNAc probes capture full binding complexes of glycosylated signaling effectors.
-
Biomarker Screening: Comparative glycosylation staining across clinical tissue cohorts uncovers candidate markers for laboratory stratification assays.
Integrated Dual Signaling Axis Linking ENO1 Glycosylation to Tumor Immune Evasion
Two synergistic O-GlcNAc-dependent pathways jointly construct an immune-suppressive tumor microenvironment niche.
Thr19-modified ENO1 accelerates glycolytic carbon flux to accumulate lactic acid waste products in extracellular space.
Extracellular lactate inhibits NK and CD8+ T cell proliferation and effector cytokine secretion capacity in co-culture models.
Ser249 glycosylation-mediated PD-L1 stabilization amplifies checkpoint inhibitory signaling upon direct tumor-T cell contact.
Combined metabolic suppression and checkpoint blockade jointly block anti-tumor immune surveillance to sustain malignant cell expansion.
This dual-site regulatory framework supplies novel molecular entry points for small molecule modulator screening in basic oncology research.
Research Application Prospects of O-GlcNAc Antibodies for Combined Immunotherapy Studies
O-GlcNAc detection reagents enable systematic mechanistic investigation of synergistic anti-tumor intervention strategies.
-
Novel Target Discovery: Antibody-based proteomic screening uncovers tumor-restricted glycosylated epitopes for antibody drug development pipelines.
-
Combination Assay Design: Dual ENO1 site mutant cell lines paired with O-GlcNAc antibody readouts evaluate checkpoint inhibitor synergy.
-
Drug Resistance Dissection: Glycosylation profiling identifies altered O-GlcNAc landscapes in PD-1/PD-L1 refractory tumor subclones.
-
Treatment Response Prediction: Tissue O-GlcNAc staining correlates with immune checkpoint compound sensitivity in cell culture models.
-
High-Throughput Compound Screening: Antibody quantitative readouts support large-scale OGT/OGA inhibitor activity assessment campaigns.
O-GlcNAc Detection Reagent Portfolio from ANT BIO PTE. LTD.
ANT BIO PTE. LTD. develops recombinant anti-O-GlcNAc antibody and matched immunoaffinity agarose beads for glycosylation proteomic research.
All reagents undergo multi-platform functional validation to deliver consistent low-background detection across cell and tissue sample matrices.
Catalog Table of O-GlcNAc Research Reagents
| Catalog Number | Full Product Name | Core Product Specifications | Available Pack Sizes |
|---|---|---|---|
| S0B0373 | O-Linked N-Acetylglucosamine Recombinant Rabbit mAb (S-R256) | Unconjugated rabbit recombinant monoclonal antibody, pan O-GlcNAc epitope recognition | 25 μL / 100 μL / 1 mL |
| S0F0009 | Anti-O-GlcNAc agarose Beads | Standard immunoaffinity resin for glycosylated peptide immunoprecipitation | 300 μL / 1 mL |
| S0F0027 | Premium Anti-O-GlcNAc agarose Beads | High-capacity affinity beads for low-abundance O-GlcNAc substrate enrichment | 300 μL / 1 mL |
Functional Performance of S0B0373 Recombinant Anti-O-GlcNAc mAb
Engineered recombinant paratopes deliver broad-spectrum recognition of O-GlcNAc modified serine and threonine residues across diverse protein backbones.
Negligible cross-reactivity against N-linked glycan structures and unmodified native polypeptides minimizes experimental background noise.
High antigen-binding affinity enables reliable detection and enrichment of low-abundance glycosylated signaling and metabolic enzymes.
Uniform recombinant manufacturing eliminates lot-to-lot signal deviation common to hybridoma polyclonal antibody preparations.
Validated compatible laboratory workflows include WB, cellular IF, formalin-fixed IHC and native protein immunoprecipitation assays.
Core Fundamental Research Applications for ANT BIO PTE. LTD. O-GlcNAc Reagents
-
Global O-GlcNAc proteome mapping via antibody IP coupled with high-resolution LC-MS/MS across tumor cell line lysates
-
Quantitative Western blot analysis tracking glycosylation shifts under OGT/OGA genetic or small molecule perturbation
-
Tissue microarray immunohistochemical staining to compare O-GlcNAc abundance in tumor and normal control specimens
-
Co-IP interactome analysis to identify binding partners of O-GlcNAc-modified transcription factors and metabolic enzymes
-
Mechanistic study of nutrient sensing signaling by monitoring O-GlcNAc fluctuations under altered glucose/glutamine culture conditions
-
Inhibitor screening assays quantifying changes in cellular O-GlcNAc levels following compound treatment of cancer cell cultures
Global Quality & Compliance Standards for ANT BIO PTE. LTD. Glycosylation Research Reagents
All anti-glycosylation antibodies and affinity beads complete multi-assay validation before commercial distribution to guarantee reproducible data output.
The full reagent portfolio integrates with pan-PTM binding buffers and histone modification antibodies for unified multi-omics analytical pipelines.
Manufacturing facilities hold ISO9001, ISO13485 and EU 98/79/EC certification for life science research reagent production.
In-house application science teams supply standardized digestion and immunoprecipitation protocols alongside peptide cross-reactivity validation datasets.
Expanded PTM reagent lines cover acetylation, crotonylation, methacrylation and methylation detection for cross-modality comparative research.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.
